Neurofibromatosis type 1: Neurofibromatosis type 1 is one of the most common human genetic diseases, occurring in approximately one of every 3000 births
In humans, resveratrol improves glycemic control in type 2 diabetes people and may cause some fat loss (Timmers et al., 2011
In addition to agonists only target to GLP-1 receptors, agonists with multiple targets now are being developed
The specific transition protocol accounts for receptor adaptation from prior dual agonist use
Biosimilars and similar biologics (for injectable GLP-1 analogues such as liraglutide, dulaglutide, and semaglutide) if companies can demonstrate comparability in structure, function, and clinical performance.[11] This framework is what enabled Indias earlier waves of affordable insulin, cancer drugs, and biologics and it is now being replicated for GLP-1 therapies